Cetuximab in metastatic colorectal cancer

V Broadbridge, Christos Karapetis, Timothy Price

    Research output: Contribution to journalReview articlepeer-review

    31 Citations (Scopus)


    Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis. Cetuximab binding to the EGF receptor is also known to augment the effects of chemotherapy and radiotherapy. Only tumors expressing wild-type KRAS respond to cetuximab and improvements in progression-free survival and overall survival are seen, whereas patients with mutant KRAS are considered to be resistant. Cetuximab is currently available worldwide for use as monotherapy or in combination with chemotherapy in first-, second- or third-line settings in metastatic colorectal cancer patients with wild-type KRAS.

    Original languageEnglish
    Pages (from-to)555-565
    Number of pages11
    JournalExpert Review of Anticancer Therapy
    Issue number5
    Publication statusPublished - May 2012


    • cetuximab
    • EGF receptor inhibitors
    • metastatic colorectal cancer


    Dive into the research topics of 'Cetuximab in metastatic colorectal cancer'. Together they form a unique fingerprint.

    Cite this